Abstract Number: 0708 • ACR Convergence 2020
Differences in Treating Knee Osteoarthritis by Clinician Specialty
Background/Purpose: Current treatment of knee osteoarthritis (OA) is focused primarily around pain relief offering sustained mobility and prioritizing symptom relief over disease progression potentially impacts…Abstract Number: 1108 • ACR Convergence 2020
Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening
Background/Purpose: To identify if biochemical markers s-Coll2-1, a peptide of type collagen and its nitrated from, s-Coll2-1NO2 are associated to knee osteoarthritis (OA), focusing on…Abstract Number: 1124 • ACR Convergence 2020
Improving Documentation Rates of Non-Pharmacologic Therapies for Knee Osteoarthritis
Background/Purpose: Musculoskeletal (MSK) pain is the leading cause of disability in older adults. Specifically, knee osteoarthritis (OA) accounts for a large burden of MSK disability…Abstract Number: 1490 • ACR Convergence 2020
Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials
Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…Abstract Number: 1968 • ACR Convergence 2020
Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Background/Purpose: Osteoarthritis (OA) is a chronic rheumatic disease, which involves pain, limited inflammation, and local destruction of the knee joint. OA pain is a major…Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…Abstract Number: 821 • 2019 ACR/ARP Annual Meeting
Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)
Background/Purpose: Osteoarthritis (OA) is by far the most common arthritis.(1) However, its chronological trend in the United Kingdom (UK) is not known. We aimed to…Abstract Number: 1307 • 2019 ACR/ARP Annual Meeting
A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain
Background/Purpose: This prospective, randomized, multi-center study was conducted to compare pain relief, functional improvement, and the safety of cooled radiofrequency ablation (CRFA) to hyaluronic acid…Abstract Number: 1326 • 2019 ACR/ARP Annual Meeting
Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Background/Purpose: Recent concerns over osteoarthritis (OA) pharmacotherapy safety have led to revision of treatment guidelines and highlight the need for therapies with good safety profiles.…Abstract Number: 1980 • 2019 ACR/ARP Annual Meeting
Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice
Background/Purpose: Osteoarthritis (OA) is a biomechanical joint disease mainly affecting articular cartilage and subchondral bone. A great variety of animal models, especially mice, are used…Abstract Number: 2179 • 2019 ACR/ARP Annual Meeting
Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort
Background/Purpose: Erosive hand osteoarthritis (EOA) is often considered a more severe form of hand OA. However, more data are needed regarding this phenotype to conclude…Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…Abstract Number: 875 • 2019 ACR/ARP Annual Meeting
Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial
Background/Purpose: Self-management is of paramount importance in non-surgical treatment of knee/hip osteoarthritis (OA). Modern technologies offer the possibility to support self-management 24/7. We developed an…Abstract Number: 1308 • 2019 ACR/ARP Annual Meeting
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Background/Purpose: Patient-reported outcomes (PROs) in knee osteoarthritis (OA) trials have been difficult to accurately measure due to heterogenous sources of pain (e.g., from comorbid conditions…
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 63
- Next Page »